As yet another proof of the large hadron collider’s value to CERN, scientists recently discovered a new type of particle using the giant mechanism. Dubbed “double heavy” or “doubly charmed,” the particle has immeasurable value to understanding principal concepts in physics. More specifically, it would help physicists look into the tiny world of quarks and better understand how it works.
In the recent New York Times article talking about the discovery, it would seem that the scientists have come up with a decidedly complicated name for the new particle. Called “Xi-cc++ (pronounced ka-sigh-see-see-plus-plus),” it would seem that much insight can be drawn from the particle with regards to how sub-atomic particles interact with one another.
For the most part, everything in the universe is made up of protons and neutrons, and the building blocks for those particles are called quarks. As of today, there is still precious little knowledge gained from studying this infinitesimally tiny ingredient. What scientists are hoping with regards to the new particle is to gain a new understanding of quarks and everything that relates to them.
Without delving too deep into physics jargon, it would seem that the new particle is nothing too radical as scientists can file it under the Standard Model, Inquisitr reports. However, every new discovery can lead to some massive changes in the field of science.
In the case of Xi-cc++, one of its biggest selling points is the improvement in accuracy of predictions by physicists with regards to other particles that have yet to be discovered. What’s more, it would seem that the nature of the particle itself is favorable for physicists since its properties make it easier to study.
Physicists are gearing up to create more Xi-cc++ particles using the large hadron collider for further studies. The scientists are also hoping to find similar particles with the same properties as Xi-cc++.


NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Neuralink Expands Brain Implant Trials with 12 Global Patients
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy 



